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Background: There is increasing interest in the non-skeletal effects of vitamin D and the relationship
between vitamin D deﬁciency and chronic conditions such as diabetes mellitus. We aimed to investigate
the relationship between surrogate indices of insulin resistance (IR), and vitamin D deﬁciency/insufﬁ-
ciency in postmenopausal Saudi women with and without metabolic syndrome.
Methods: The study population consisted of 300 postmenopausal women aged 46e88 years enrolled
consecutively from women attending the Outpatient Clinics of King Abdulaziz University Hospital. De-
mographic, anthropometric, and biochemical parameters were recorded. Data were analyzed for women
with and without metabolic syndrome.
Results: Abdominal obesity, IR, and hypovitaminosis D were highly prevalent within our population
sample. Of the components used to deﬁne metabolic syndrome; waist circumference, serum triglycerides
(TG), high density lipoprotein-cholesterol, and fasting blood glucose (FBG) were signiﬁcantly related with
all surrogate measures of IR. Signiﬁcant inverse correlations were found between serum vitamin D and
serum TG, FBG, and diastolic blood pressure, within the study cohort.
Conclusions: These observations suggest that hypovitaminosis D may be associated with the risk of
developing metabolic syndrome. Interrelationships between IR, metabolic syndrome, and hypovitami-
nosis D are of particular interest in Saudi population, given the high prevalence of these conditions in this
region.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
There is increasing interest in the non-skeletal effects of
vitamin D and the relationship between vitamin D deﬁciency and
diseases such as obesity, diabetes mellitus, and coronary artery
diseases [1].AHA/NHLBI, American Heart
BMI, body mass index; DBP,
HDL-C, high density lipopro-
sment for insulin resistance;
Hospital; LDL-C, low-density
QUICKI, quantitative insulin
; SD, standard deviation; TG,
BY-NC-ND license (http://
close.
32; fax: þ966 2 6643499.
).
Published by Elsevier Inc. All rightSerum 25-hydroxyvitamin D3 (25(OH)D3) concentrations
reﬂect vitamin D status derived from diet, exposure of the skin to
sunlight, as well as the conversion of vitamin D from adipose stores
in the liver. Therefore, it is considered the most appropriate indi-
cator of overall vitamin D status [2]. Serum concentrations of
25(OH)D < 50 nmol/L are reported to be associated with decreased
insulin sensitivity and metabolic syndrome [3].
Insulin resistance (IR) and hyperinsulinemia often precede 2
diabetes [4]. Current interest in IR and metabolic syndrome is
because of their increasing prevalence in many populations and the
associated high rate of mortality and morbidity due to cardiovas-
cular disease, even in non-diabetic subjects [5]. Previous reports
suggest a positive association between IR and markers of inﬂam-
mation, such as C-reactive protein [6]. It is possible that chronic
inﬂammation may represent a triggering factor in the origin of IR
and subsequently type 2 diabetes [7].
The assessment of IR can be made by evaluating the peripheral
insulin sensitivity using in vivo methods such as the pancreatic
suppression test and the hyperinsulinemic-euglycemic clamps reserved.
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expensive methods suitable only for studies with a small number of
subjects [9]. For epidemiologic and clinical studies, simpler, indirect
methods have been advocated for quantiﬁcation of IR with different
mathematical formulas. Such methods include measurement of
fasting plasma insulin levels, the homeostasis model assessment for
insulin resistance (HOMA-IR) [10], the quantitative insulin sensi-
tivity check index (QUICKI) [11] and McAuley [12] indices.
Although the prevalence of metabolic syndrome in adults living
in the Kingdom of Saudi Arabia has been investigated [13], no study
has examined the relationship between surrogate measures of IR
and metabolic syndrome. Furthermore, it remains uncertain
whether the presence of metabolic syndrome and IR are linked to
the greater rates of hypovitaminosis D observed in Saudi post-
menopausal women [14,15]. Therefore, we aimed to investigate the
relationship between HOMA-IR, QUICKI, McAuley indices, and
vitamin D deﬁciency in Saudi postmenopausal women with and
without metabolic syndrome.Methods
The study population consisted of 300 postmenopausal women
aged 46e88 years enrolled consecutively from women attending
the Outpatient Clinics of King Abdulaziz University Hospital (KAUH)
during visits for education purposes, or routine checkups, or for
evaluation of cardiovascular risk factors.
Postmenopausal status was deﬁned as cessation of menstrua-
tion for at least 1 year. None of the patients had any the following
disorders: liver or renal disease, inﬂammatory disease, vascular
disease (i.e., peripheral vascular disease, cerebro-vascular disease),
endocrine disease, established osteoporosis, or on any form of drug
treatment with a possible effect on bone metabolism, including:
bisphosphonate, or estrogen replacement therapy, oral contracep-
tives, statins, aspirin, antioxidants, vitamin D or calcium
supplementations.
The studywas approved by the ethical review board of KAUH. All
subjects gave their informed consent for the study, which was
performed in accordance with the guidelines proposed in the
Declaration of Helsinki.
Participants were questioned about their age, age at the onset of
menopause, socioeconomic status, family history of osteoporosis,
lifestyle behaviors, including cigarette smoking and physical ac-
tivity level, and frequency of exposure to sunlight. Smoking habit
was categorized as non-smoker, former smoker, and current
smoker. Physical activity was self-graded by the participant ac-
cording to the number of episodes of exercise undertaken per week
and were categorized as active (3 times/week) or inactive (<3
times/week) according to the recommendations of the American
Heart Association consensus statement on primary prevention of
coronary diseases and from the USA Surgeon General’s report [16].
Body weight was measured to the nearest 0.1 kg. Height was
determined to the nearest cm. Body mass index (BMI) was calcu-
lated as the weight (kg) divided by the square of height (m2). Waist
circumferencewasmeasured at the narrowest part of the abdomen,
that is, at the natural indentation between the 10th rib and the iliac
crest (minimum waist).
Arterial blood pressure levels were measured in the right arm
using a standard mercury sphygmomanometer (Baumanometer,
USA). Two systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) readings were recorded at 5-min intervals and averaged
for analysis. To avoid subjective error, all measurements were taken
by the same trained staff.
Fasting blood samples were taken after fasting for at least 12 h.
Venous blood samples were taken from an antecubital vein andplaced into plain, or heparinized tubes. Tubes were centrifuged at
3000g for 10 min.
Serum fasting blood glucose (FBG), creatinine, and lipids levels
(triglycerides (TG), total cholesterol, and high density lipoprotein
(HDL)-cholesterol) were determined by an automatic colorimetric
method (Ortho-Clinical Diagnostics, Johnson & Johnson Co, USA).
Serum low-density lipoprotein (LDL)-cholesterol values were
estimated using the following formula: total cholesterol (mmol/L)
e HDL-cholesterol (mmol/L) e triglycerides (mmol/L)/2.2. Serum
insulin concentrations were measured by a radioimmunoassay
(DiaSorin, Italy). Serum 25(OH)D was quantiﬁed by a chem-
iluminescence method using a LIASON autoanalyzer (DiaSorinInc,
Stillwater, MN, USA) and all samples were analyzed in duplicate.
Subjects with serum 25(OH)D levels <50 nmol/L were categorized
as having 25(OH)D deﬁciency [17]. Intact parathyroid hormone
(PTH) was measured with an electrochemiluminescent assay using
COBAS e411-Hitachi immunoassay analyzer (Roche Diagnostics
GmbH, D-68298 Mannheim, Germany).
We used the American Heart Association/National Heart, Lung
and Blood Institute (AHA/NHLBI) deﬁnition of metabolic syndrome
[18]; the presence of abdominal obesity (>88 cm inwomen) with at
least two of the following: 1) high triglycerides (1.7 mmol/L,
[150 mg/dl]), 2) low HDL cholesterol (<1.04 mmol/L [40 mg/dl] in
men and<1.29 mM/L [50 mg/dl] inwomen), 3) high blood pressure
(130/85 mm Hg or current antihypertensive medications), and 4)
high fasting glucose (6.1 mmol/L [110 mg/dl]).
Indirect indices of insulin resistance include: HOMA-IR, QUICKI,
and McAuley formulas. HOMA-IR was calculated from the fasting
insulin (mU/ml)  fasting glucose (mmol/L)/22.5. The QUICKI index
is based on the logarithmic transformation: 1/(log fasting insulin
[mU/ml] þ log fasting glucose [mg/dl]). The McAuley index was
calculated: exp [2.63  0.28 ln (insulin in mU/L)  0.31 ln (TG in
mmol/L)]. Patients were considered as insulin resistant when
McAuley index5.8, HOMA-IR2.6 and QUICKI0.33 [12,19]. Also,
TG/HDL-C ratio has been reported to be closely related to insulin
resistance among nondiabetic individuals [20].
Means and standard deviations (SD) were calculated for
continuous variables. Difference between those with metabolic
syndrome and nonemetabolic syndrome groups was estimated
using was analyzed using an independent 2 sample t-test orManne
Whitney U-test for continuous variables, and the chi-square test for
categorical variables. Pearson’s correlations were performed to
examine the associations between IR measures and metabolic
syndrome components. A multiple stepwise regression analysis
was performed to identify variables that independently predicted
IR measures. An interaction of independent variables was assessed.
All analyses were performed in SPSS (version 21.5). All reported
p values were from two-sided tests and compared to a signiﬁcant
level of 5%.Results
The clinical characteristics of the 300 postmenopausal women
are shown in Table 1. The subjects with metabolic syndrome re-
ported a signiﬁcantly lower level of physical activity compared to
the control group (p< 0.05). However, overweight and obesity were
also highly prevalent among the group without metabolic syn-
drome, 41% were overweight and 51% were obese according to BMI
values and 65% had waist circumference >88 cm. Most participants
were poorly educated housewives, living in apartments, and had
limited exposure to ultraviolet sunlight. Physical inactivity was
more prevalent among women with metabolic syndrome than
those without metabolic syndrome (46% vs. 32%; p< 0.05) whereas
more women without metabolic syndrome were exercising 3
Table 1
Clinical characteristics according to the presence or absence of metabolic syndrome in 300 postmenopausal women
Postmenopausal women without MetS (n ¼ 129) Postmenopausal women with MetS (n ¼ 171) p value
Age (years) 59.4  0.8 60.3  0.6 0.491
Age at menopausal (years) 49.9  0.5 50.5  0.4 0.722
Body weight (kg) 72.2  1.3 77.6  1.1 <0.0001
Body height (cm) 151.7  0.5 152.9  0.4 0.061
BMI (kg/m2) 31.3  0.5 33.2  0.4 0.001
BMI classes 0.005
Normal (18.5 kg/m224.9 kg/m2) 10 (8) 9 (5)
Overweight (25 kg/m2e29.99 kg/m2) 54 (41) 43 (25)
Obese (30 kg/m2) 65 (51) 119 (70)
Waist circumference (cm) 95.8  1.4 103.2  1.7 <0.0001
Waist circumference classes <0.0001
Waist circumference >88 cm 83 (65) 171 (100)
SBP (mm Hg) 128.0  1.9 140.5  0.9 <0.0001
DBP (mm Hg) 76.3  1.0 79.9  1.0 0.007
Marital status <0.05
Married 72 (56) 107 (63)
Widowed 33 (25) 53 (31)
Divorced 24 (19) 11 (6)
Parity 0.278
0 5 (4) 9 (5)
1 3 (2) 4 (4)
2 2 (1) 4 (2)
3 10 (8) 6 (4)
4 109 (85) 148 (87)
Education level 0.161
Illiterate 53 (41) 89 (52)
Intermediate 41 (32) 37 (22)
High school 10 (7) 19 (11)
University 25 (20) 26 (15)
Occupation 0.158
House wife 121 (93) 167 (98)
Administrative 6 (5) 2 (1)
Director/physician 2 (2) 2 (1)
Type of residency 0.545
Traditional housing 26 (20) 37 (22)
Apartment 79 (62) 103 (60)
Villa 24 (19) 31 (18)
Exposure to sunlight 0.222
<1 time 89 (70) 129 (75)
1e2 times 37 (28) 32 (19)
>3 times 3 (2) 10 (6)
Veil type 0.336
Covering hair only 37 (28) 52 (30)
Eyes shown only 85 (66) 104 (61)
Full cover 7 (6) 15 (9)
Physical activity 0.033
<1 time 41 (32) 78 (46)
1e2 times 23 (17) 33 (19)
3 times 65 (51) 60 (35)
Smoking status 0.826
Non-smoker 120 (94) 161 (94)
Former smoker 3 (2) 6 (4)
Current smoker 6 (4) 4 (2)
Data are given as the mean  SD or as the number of subjects with percentages given in parentheses, as appropriate. Categorical data are compared by c2 test, continuous
variables are compared by unpaired t-test. BMI: body mass index, DBP: diastolic blood pressure, SBP: systolic blood pressure.
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(51% vs. 30%; p < 0.05).
In our cohort, 57% of subjects met diagnostic criteria for meta-
bolic syndrome displaying higher body weight, BMI, waist
circumference, SBP, and DBP values (p < 0.01). In addition, the
metabolic syndrome group had higher serum TG, FBG, insulin,
HOMA-IR, QUICK-I, and McAuley index levels (p < 0.001) as
compared to the nonemetabolic syndrome group despite similar
serum cholesterol levels (Table 2). Therewas awide range for the IR
measures in the entire cohort; HOMA-IR (0.3e36.7), QUICK-I (0.24e
0.48), and McAuley index (2.6e13.3). Our results showed that 64%
of total populationwas IR according to HOMA-IR index, 70%were IR
according to QUICK-I, and 47% were IR according to McAuley index.
Those in the metabolic syndrome group had a mean TG/HDL ratiothat was almost double the value of those in the non-metabolic
syndrome group (p < 0.0001).
Bivariate correlations between IR measures and components of
the metabolic syndrome were evaluated for the whole population
(Table 3). HOMA-IR index was related to a greater number of the
metabolic syndrome components than the other 2 IR measures.
QUICK-I index presented fewer signiﬁcant, but less strong, corre-
lations with the remaining IR measures. The HOMA-IR index was
positively associated with waist circumference (r ¼ 0.213, p < 0.05)
and serum TG (r ¼ 0.307, p < 0.0001) and negatively associated
with serum HDL-C (r ¼ 0.202, p < 0.05). QUICK-I index was
negatively associated with waist circumference (r ¼ 0.285,
p < 0.0001), TG (r ¼ 0.311, p < 0.0001), FBG (r ¼ 0.556,
p < 0.0001), and positively associated with HDL-C (r ¼ 0.211,
Table 2
Biochemical parameters according to the presence or absence of metabolic syndrome in 300 postmenopausal women
Postmenopausal women without MetS (n ¼ 129) Postmenopausal women with MetS (n ¼ 171) p value
TC (mmol/L) 4.68  0.1 4.66  0.1 0.953
TG (mmol/L) 1.34  0.1 2.2  0.1 <0.0001
HDL-C (mmol/L) 1.47  0.0 1.2  0.0 <0.0001
LDL-C (mmol/L) 2.56  0.1 2.46  0.1 0.270
TG/HDL 0.99  0.1 2.01  0.1 <0.0001
FBG (mmol/L) 5.81  0.2 8.3  0.3 <0.0001
Serum insulin (mU/ml) 13.1  0.8 15.9  0.8 0.015
HOMA-IR 3.62  0.4 5.92  0.4 <0.0001
QUICK-I 0.33  0.0 0.31  0.0 <0.0001
McAuley index 6.92  0.2 5.66  0.1 <0.0001
Serum creatinine (mmol/L) 68.3  1.5 72.4  2.4 0.882
Intact PTH (pmol/L) 5.8  0.4 5.8  0.3 0.287
Serum 25 hydroxyvitamin D (nmol/L) 31.1  2.1 31.2  1.6 0.683
Serum vitamin D deﬁciency (<50 nmol/L) 99 (77) 140 (82) 0.505
Data are given as the mean  SD or as the number of subjects with percentages given in parentheses, as appropriate. Continuous variables are compared by unpaired t-test.
FBG: fasting blood glucose, HDL-C: high density lipoprotein-cholesterol, HOMA-IR: homeostasis model for insulin resistance, LDL-C: low density lipoprotein-cholesterol, NS:
not signiﬁcant, PTH: parathyroid hormone, QUICK-I: quantitative insulin sensitivity check index, TC: total cholesterol, TG: triglycerides.
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HDL-C (r ¼ 0.341, p < 0.0001) and negatively associated with waist
circumference (r ¼ 0.212, p < 0.05), serum TG (r ¼ 0.688,
p < 0.0001), and FBG (r ¼ 0.330, p < 0.0001).
Because various factors could affect IR measures, we performed
multivariate regression analyses and included all potential cova-
riates (Table 4). The ﬁrst model conﬁrmed an independent rela-
tionship between serum levels of TG, FBG, insulin, and QUICK-I with
HOMA-IR accounting for 90.0% of the variation. The second model
showed that serum TG, HDL-C, TG/HDL-C, FBG, and QUICK-I levels
were signiﬁcant independent predictors of McAuley index
(R2 ¼ 94.2%). As shown in the third model serum TG, HDL-C, TG/
HDL-C, FBG, McAuley index, and HOMA-IR were highly signiﬁcant
and independent predictors for QUICK-I, it accounted for 94.1% of
the variation.
Vitamin D deﬁciency was identiﬁed in 80% of the entire cohort
but was more prevalent in the metabolic syndrome group
compared to the non-metabolic syndrome group (82% vs. 77%)
without a statistically signiﬁcant difference in the mean values ofTable 3
Correlation analysis of IR measures withmetabolic syndrome components and other
biochemical variables in 300 postmenopausal women
HOMA-IR QUICK-I McAuley index
r p r p r p
Waist circumference 0.285 <0.0001 L0.285 <0.0001 L0.309 <0.0001
TG 0.361 <0.0001 L0.311 <0.0001 L0.708 <0.0001
HDL-C L0.202 <0.0001 0.211 <0.0001 0.369 <0.0001
FBG 0.579 <0.0001 L0.556 <0.0001 L0.330 <0.0001
SBP 0.005 0.937 0.038 0.514 0.027 0.641
DBP 0.043 0.454 0.032 0.582 0.026 0.659
TG/HDL-C 0.353 <0.0001 L0.272 <0.0001 L0.679 <0.0001
LDL-C L0.184 0.001 0.130 0.025 0.070 0.228
TC L0.165 0.004 0.039 0.500 0.049 0.396
Insulin 0.878 <0.0001 L0.661 <0.0001 L0.830 <0.0001
Body weight 0.143 0.013 L0.143 0.013 L0.156 0.007
BMI 0.152 0.008 0.105 0.071 L0.158 0.006
Age 0.077 0.182 0.077 0.186 0.136 0.018
Menopausal age L0.124 0.032 0.057 0.324 0.069 0.235
Vitamin D 0.038 0.509 0.032 0.580 0.167 0.029
Pearson’s correlations were performed to examine the associations between IR
measures and metabolic syndrome components. Signiﬁcant correlations are shown
in bold font. BMI: bodymass index, DBP: diastolic blood pressure, FBG: fasting blood
glucose, HDL-C: high density lipoprotein-cholesterol, HOMA-IR: homeostasis model
for insulin resistance, LDL-C: low density lipoprotein-cholesterol, QUICK-I: quanti-
tative insulin sensitivity check index, SBP: systolic blood pressure, TC: total
cholesterol, TG: triglycerides.serum vitamin D (p > 0.05). The relationship between serum
vitamin D concentrations to insulin sensitivity was investigated in
the study cohort. There was a signiﬁcant inverse correlation be-
tween serum vitamin D with 3 components of the metabolic syn-
drome; serum TG (r ¼ 0.183, p < 0.05), FBG (r ¼ 0.192, p < 0.05),
and DBP (r ¼ 0.130, p < 0.05) levels. In addition, serum vitamin D
was positively correlated with McAuley index (r ¼ 0.167, p < 0.05).
However, this association was shown not signiﬁcant after multi-
variate analysis. No signiﬁcant correlations were observed between
serum vitamin D concentration and either HOMA-IR or QUICK-I. Of
all these variables, DBP was shown to be the only predictive vari-
able, accounting for 1.4% of variation in serum vitamin D concen-
trations (b ¼ 0.118, p < 0.05). However, the prevalence of IR was
signiﬁcantly higher (p < 0.05) among vitamin D deﬁcient women,
as categorized by serum circulating levels <50 nmol/L, by all IR
measures (64% according to HOMA-IR, 70% according to QUICK-I,
and 48% according to McAuley index).Discussion
The results presented show that abdominal obesity, IR, and
hypovitaminosis D were highly prevalent among our cohort of 300
postmenopausal women with and without metabolic syndrome asTable 4
Multivariate analysis of IR measures with independent variables in 300 post-
menopausal women
Predictor variable b p value 95% CI for b
HOMA-IR Serum insulin 0.891 <0.0001 0.394 0.451
Total R2 ¼ 90.0% Serum TG 0.064 0.001 0.540 0.132
Serum FBG 0.525 <0.0001 0.806 0.967
QUICK-I 0.177 <0.0001 14.802 34.245
QUICK-I Serum FBG 0.484 <0.0001 0.007 0.005
Total R2 ¼ 94.1% Serum TG 0.619 <0.0001 0.020 0.027
Serum HDL-C 0.105 <0.0001 0.017 0.007
TG/HDL-C 0.256 <0.0001 0.011 0.005
HOMA-IR 0.205 <0.0001 0.001 0.002
McAuley index 0.885 <0.0001 0.019 0.021
McAuley index Serum FBG 0.329 <0.0001 0.161 0.198
Total R2 ¼ 94.2% Serum TG 0.686 <0.0001 1.291 1.033
Serum HDL-C 0.134 <0.0001 0.485 0.874
TG/HDL-C 0.286 <0.0001 0.282 0.519
QUICK-I 0.852 <0.0001 36.485 39.467
95% CI: conﬁdence intervals, b ¼ standardized regression coefﬁcient, FBG: fasting
blood glucose, HDL-C: high density lipoprotein-cholesterol, HOMA-IR: homeostasis
model for insulin resistance, QUICK-I: quantitative insulin sensitivity check index,
R2 ¼ percent variance explained by each variable, TG: triglycerides.
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drome observed in our cohort may have obscured the impact of
other coronary risk factors. Whilst none of the subjects had clinical
evidence of hypertension, diabetes, coronary artery disease, or
dyslipidemia (according to the cutoff values of the AHA/NHLBI
deﬁnition of metabolic syndrome), which although are not
apparent at current presentation may appear later in life. Several of
these conditions are known to inﬂuence insulin sensitivity [21], for
example abdominal obesity which is also an important coronary
risk factor, both directly and through its association with other
coronary risk factors [22]. The presence of IR itself appears to be the
result of a complex interplay of genetic factors with environmental
factors. Taking these ﬁndings for the majority of the study cohort
together with their old age, sedentary lifestyle habits, low tomiddle
socioeconomic status, and limited exposure to sunlight, it may be
linked to the presence of IR as well as hypovitaminosis D. Since it
has been proposed that 25(OH)D deﬁciency was associated with
decreased peripheral insulin action, either via reduced insulin re-
ceptor expression or via impaired signaling downstream of the
insulin receptor [23].
Metabolic syndrome is deﬁned by a clustering of cardiovas-
cular risk factors that include central adiposity, hypertension,
dyslipidemia and impaired glucose metabolism. Indeed IR is
considered the key feature of metabolic syndrome and is asso-
ciated with several component features of metabolic syndrome
[21]. Of these component features; waist circumference, serum
TG, HDL-C, and FBG were signiﬁcantly related to all surrogate
measures of IR. The relationship with serum TG, HDL-C, and FBG
were independent of confounding factors with at least 2 IR
measures. Thus our data suggest that surrogate markers of IR
may help to identify subjects with some components of the
metabolic syndrome and who may be at high future risk of
metabolic imbalances. Similar results have been reported pre-
viously [24]. Even though the authors did not include plasma
insulin and glucose values in the regression analysis, as they
were already included in the HOMA-IR formula. Identifying
subjects with IR is difﬁcult because insulin sensitivity is difﬁcult
to quantify accurately. Therefore, early screening of IR using any
of the surrogate markers might be useful in a high-risk popu-
lation (for example our cohort of postmenopausal women) who
are at increased risk of developing diabetes. Strong independent
correlations between the 3 IR indices also suggest validity of all
these measures of IR. Multivariate analysis has previously shown
that TG is an independent predictor of the 3 IR measures.
Hypertriglyceridemia is closely linked to IR [25].
Vitamin D can affect tissues that are not involved in calcium
homeostasis and bone metabolism, such as its immune modula-
tory functions and its implication in systemic inﬂammation
[23,26]. Therefore, vitamin D deﬁciency is proposed to be a risk
factor for a number of conditions. Furthermore, vitamin D could
play a role in the pathogenesis of type 2 diabetes, by affecting
insulin sensitivity [27,28]. Inverse correlations were demonstrated
between serum vitamin D with 3 components of metabolic syn-
drome; serum TG, FBG, and DBP, amongst the whole population.
These observations indicate that hypovitaminosis D is associated
with an increased risk of metabolic syndrome. Similar results have
been found in postmenopausal women conﬁrming an association
of vitamin D status with metabolic syndrome [29]. Other studies
failed to show a signiﬁcant association between vitamin D and
metabolic syndrome [30]. DBP accounted for 1.4% of changes in
serum vitamin D level (b ¼ 0.118, p < 0.05). It has been reported
previously that cardiovascular disease and hypertension are
related to serum Vitamin D status [31]. There is also a growing
evidence that vitamin D has a preventive role in the development
of heart disease [32].It appears that vitamin D may stimulate the expression of the
insulin receptor in peripheral tissues and thereby increase glucose
transport [33]. Insulin-mediated processes are calcium dependent
and therefore may be indirectly inﬂuenced by vitamin D status
[34]. There is some evidence suggesting that vitamin D deﬁciency
might be involved in the pathogenesis of insulin resistance and the
metabolic syndrome [1,35]. However the exact mechanisms
remain unknown. Inﬂammation is believed to accelerate the
pathogenesis of metabolic syndrome and through local activation
of 25(OH)D to its active form by tissue macrophages, which can
open calcium channels and lead to calciﬁcation in vascular smooth
muscle cells [36]. Calcium ion ﬂuxes have an important role in
regulating secretory mechanisms including insulin secretion.
Vitamin D may play a role in the regulation of b-cell function [23].
Others have suggested vitamin D deﬁciency and the associated
secondary hyperparathyroidism, are among endocrine de-
rangements of obesity, to be implicated as risk factors for meta-
bolic syndrome [37].
IR is a complex disorder that has recently been proposed to be
important in the pathogenesis of a number of conditions other than
metabolic syndrome, including hypovitaminosis D [35]. Data from
the Framingham Offspring Study show an inverse association of
25(OH)D with HOMA-IR index in non-diabetic adults [38]. In our
study, subjects in the vitamin D deﬁcient group had a signiﬁcantly
higher prevalence of IR than the vitamin D sufﬁcient group
(p < 0.05). Thus, hypovitaminosis D may be linked to IR and the
variables that can integrate the abnormalities of the metabolic
syndrome and cardiometabolic function. The McAuley index was
the only IR measure showing positive correlation with serum
vitamin D. However, this association lost signiﬁcance in the mul-
tiple regression analysis, suggesting either the absence of an asso-
ciation between these two variables or insufﬁcient power of our
study to detect an existing association.
Because of our cross-sectional study design the causality of re-
lationships between parameters cannot be proven; a future longi-
tudinal study that addresses the association of insulin resistance
with hypovitaminosis D may therefore be of value. It should also be
noted that all IR surrogate markers are based on the estimation of
insulin effects on glucose metabolism which do not always assess
the broader metabolic consequences of insulin resistance, e.g. ab-
normalities in lipid metabolism. Furthermore, the different deﬁni-
tions of the metabolic syndrome have led to some confusion and
inconsistency between studies. One difﬁculty has been that the
conceptual framework used to deﬁne metabolic syndrome has not
been agreed. Given the high mean fasting blood glucose value
among postmenopausal women with metabolic syndrome, it
would have been useful to conduct oral glucose tolerance test, or
hemoglobin A1c to make a formal diagnosis of diabetes mellitus in
our study population.
Interrelationships among IR, metabolic syndrome, and hypo-
vitaminosis D are of particular interest in the Saudi population.
Because of the high prevalence of diabetes in this population and
the high risk of cardiovascular diseases among those with diabetes,
the need for early cardiovascular risk factor modiﬁcation is greatly
increased. In conclusion, our ﬁndings suggest that hypovitaminosis
D might be an important factor in IR and metabolic syndrome. In
Saudi Arabia, postmenopausal women, may be at risk of inadequate
vitamin D status because of limited exposure to sunlight and, lower
dietary intake [1].Acknowledgments
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